CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen

Roel Ruiter, Monique Bijl, Ron van Schaik, Els Berns, Bert Hofman, Jan Willem Coebergh, Charlotte Noord, Loes Visser, Bruno Stricker

Research output: Contribution to journalArticleAcademicpeer-review

40 Citations (Scopus)


Aims: Variant alleles of the CYP2C19 gene were recently associated with survival in breast cancer patients on tamoxifen therapy. CYP2C19 is one of the enzymes involved in the metabolism of tamoxifen into active metabolites. We investigated the hypothesis that CYP2C19*2 and *3 variants, known for their lack of enzyme activity, are associated with an increased breast cancer mortality rate in patients using tamoxifen. Materials & methods: In the prospective population based Rotterdam study, the association between CYP2C19*2 carriers and breast cancer mortality was studied among 80 incident users of tamoxifen. Survival was analyzed with life tables and Cox regression analysis, with drug exposure as a time-dependent variable. Adjustments were made for calendar time, average tamoxifen dose, age, the indication for tamoxifen, CYP2D6 genotype and concomitant use of CYP2C19 inhibitors or inducers. Results: In patients on tamoxifen, CYP2C19*2 carriers were associated with a significantly longer breast cancer survival rate than patients with the wild-type (hazard ratio 0.26, 95%CI: 0.08-0.87). Conclusion: This study suggests that CYP2C19 genotype may possibly be a predictive factor for survival in breast cancer patients using tamoxifen.
Original languageUndefined/Unknown
Pages (from-to)1367-1375
Number of pages9
Issue number10
Publication statusPublished - 2010

Cite this